Fast Parameters Estimation in Medication Efficacy Assessment Model for Heart Failure Treatment

Introduction. Heart failure (HF) is a common and potentially fatal condition. Cardiovascular research has focused on medical therapy for HF. Theoretical modelling could enable simulation and evaluation of the effectiveness of medications. Furthermore, the models could also help predict patients' cardiac response to the treatment which will be valuable for clinical decision-making. Methods. This study presents a fast parameters estimation algorithm for constructing a cardiovascular model for medicine evaluation. The outcome of HF treatment is assessed by hemodynamic parameters and a comprehensive index furnished by the model. Angiotensin-converting enzyme inhibitors (ACEIs) were used as a model drug in this study. Results. Our simulation results showed different treatment responses to enalapril and lisinopril, which are both ACEI drugs. A dose-effect was also observed in the model simulation. Conclusions. Our results agreed well with the findings from clinical trials and previous literature, suggesting the validity of the model.

[1]  G. Guyatt.  The Treatment of Heart Failure , 1986, Drugs.

[2]  N. Ikeda,et al.  Mathematical model of cardiovascular mechanics for diagnostic analysis and treatment of heart failure: Part 2 analysis of vasodilator therapy and planning of optimal drug therapy , 2006, Medical and Biological Engineering and Computing.

[3]  M. Pfeffer,et al.  Pulsatile Hemodynamics in Congestive Heart Failure , 2001, Hypertension.

[4]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[5]  I. Enström,et al.  Comparison between enalapril and lisinopril in mild-moderate hypertension: a comprehensive model for evaluation of drug efficacy. , 1992, Blood pressure.

[6]  G. C. Carlson,et al.  The treatment of heart failure. , 1949, The Mississippi doctor.

[7]  E. Braunwald,et al.  A comparison of the effects of vasodilator stimuli on peripheral resistance vessels in normal subjects and in patients with congestive heart failure. , 1968, The Journal of clinical investigation.

[8]  M. Ursino,et al.  Role of short-term cardiovascular regulation in heart period variability: a modeling study. , 2003, American journal of physiology. Heart and circulatory physiology.

[9]  A. Leon,et al.  Lisinopril dose-response relationship in essential hypertension. , 1989, British journal of clinical pharmacology.

[10]  B. Jarvis,et al.  Lisinopril , 2000, Drugs.

[11]  D. Renlund,et al.  Lisinopril Lowers Cardiac Adrenergic Drive and Increases, 8‐Recept or Density in the Failing Human Heart , 1993, Circulation.

[12]  K. Swedberg,et al.  Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.

[13]  P. Poole‐Wilson.  Heart failure. Unfinished business--a possible role for vasodilators. , 1993, International journal of cardiology.

[14]  Simulate Heart Failure by a Mathematical Model , 2009, 2009 3rd International Conference on Bioinformatics and Biomedical Engineering.

[15]  Nancy M Albert,et al.  Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. , 2006, JAMA.

[16]  H. D. del Portillo,et al.  Efficacy and safety of valsartan compared with enalapril at different altitudes. , 2000, International journal of cardiology.

[17]  E. Kosenko,et al.  Specific and Pronounced Impacts of Lisinopril and Lisinopril Plus Simvastatin on Erythrocyte Antioxidant Enzymes , 2010, Journal of clinical pharmacology.

[18]  H. Haller,et al.  Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial , 2008, Journal of hypertension.

[19]  R. Hermida,et al.  Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial. , 2008, Clinical therapeutics.

[20]  B. Massie,et al.  Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. , 1997, American heart journal.

[21]  A. Cohen-Solal,et al.  Treatment practices in heart failure with preserved left ventricular ejection fraction: a prospective observational study. , 2007, International journal of cardiology.

[22]  A. Smit,et al.  Effects of amlodipine and lisinopril on intima–media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial) , 2004, Journal of hypertension.

[23]  M. Diaz-Insua,et al.  Modeling and simulation of the human cardiovascular system with bond graph: A basic development , 1996, Computers in Cardiology 1996.

[24]  K. Dickstein,et al.  A Comparison of Hypotensive Responses After Oral and Intravenous Administration of Enalapril and Lisinopril in Chronic Heart Failure , 1987, Journal of cardiovascular pharmacology.

[25]  J. Vitale,et al.  Systolic heart failure. , 2010, The New England journal of medicine.

[26]  Wen Shu-xiang.  Efficacy of irbesartan versus enalapril in treatment of mild and Moderate Hypertension , 2009 .

[27]  D. V. van Veldhuisen,et al.  The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure. , 2010, International journal of cardiology.

[28]  M. Anastasiou-Nana,et al.  Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. High Enalapril Dose Study Group. , 2000, Journal of the American College of Cardiology.

[29]  Daniel Levy,et al.  Systolic Blood Pressure, Diastolic Blood Pressure, and Pulse Pressure as Predictors of Risk for Congestive Heart Failure in the Framingham Heart Study , 2003, Annals of Internal Medicine.

[30]  M David Tilson,et al.  The polymorphonuclear leukocyte and the abdominal aortic aneurysm: a neglected cell type and a neglected disease. , 2005, Circulation.